Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS?

View original at nasdaq.com
D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS? Shares of D-Wave QuantumQBTS struggled from January to mid-May, falling 32.3% amid the uncertainty surrounding its pace of commercialization, uneven revenue recognition and rising competition across quantum computing…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • D-Wave has $588 million in liquidity.

    60% confidence
  • D-Wave's roadmap targets approximately 175 physical qubits by 2028, 10 logical qubits by 2030, and 100 logical qubits by 2032.

    60% confidence
  • QBTS is projected to report 2026 earnings growth of 72.1% on revenue growth of 63.3% from the 2025 reported figure.

    60% confidence
  • A substantial portion of 2026 revenues will be recognized in the second half of the year as large system deals progress toward delivery and installation.

    60% confidence
  • D-Wave's collaboration with Shionogi produced a tenfold increase in desirable drug-like molecules versus classical machine learning approaches.

    60% confidence
  • QBTS currently carries a Zacks Rank #3 (Hold).

    60% confidence
  • D-Wave's Advantage2 quantum system outperformed classical nodes in mining operations on the Postquant Labs blockchain testnet.

    60% confidence
  • D-Wave's forward 12-month P/S ratio of 179.30x is far above the sector average of 6.77x, above IonQ's 74.72x, but below Rigetti Computing's 244.38x.

    60% confidence
  • Q1 2026 bookings surged 1,994% year over year to a record $33.4 million, supported by a $20 million system sale to Florida Atlantic University and a $10 million two-year QCaaS agreement with a Fortune 100 company.

    60% confidence
  • D-Wave's sales pipeline more than doubled sequentially during Q1 2026.

    60% confidence
  • Remaining performance obligations climbed 563% year over year to $42.4 million.

    60% confidence
  • D-Wave faces execution risks tied to system-sale timing, backlog conversion, rising operating expenses from the Quantum Circuits acquisition, and intense competition with many commercial applications still emerging.

    60% confidence

Data points we hold from this source

D-Wave Quantum Inc. · market share179.30 price_to_sales_ratio
D-Wave Quantum Inc. · cash588 USD
D-Wave Quantum Inc. · backlog33.4 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com